Signum Biosciences Awarded Two Additional NIH Grants for Development of Topical Therapeutics

PRINCETON, New Jersey, September 20, 2010 - Signum Biosciences, Inc. was recently awarded two Small Business
Innovation Research (SBIR) Phase I grants by the National Institute of
Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a division of the
NIH, totaling over US$684,000 for development of novel G-protein coupled
receptor (GPCR) modulating therapeutics designed to treat common skin
disorders.

Through the first SBIR grant, Signum will develop anti-inflammatory
agents to reduce chronic redness (erythema) associated with eczema, atopic
dermatitis, and rosacea. Access to more effective therapies is of significant
importance to a large patient population suffering from chronic skin disease.
Signum's Signal Transduction Modulator (STM) technology has already
demonstrated significant reduction of redness in a double-blinded placebo
controlled clinical study.

A second SBIR grant was awarded to fund Signum's identification and
development of multi-functional, safe, topical anti-acne therapeutics. Acne
is the most common disorder of the human skin and affects up to 80% of
individuals at some point in their lives. Signum's STM technology has shown
potential to reduce both inflammation and infection associated with acne.

"We are proud to be awarded additional grants by the NIH, further
supporting our unique approach and scientific direction. Our objective
continues to be development of our technology with the goal of improving
quality of life for the large number of patients suffering from skin
disease," stated Dr. Braham Shroot, Chief Executive Officer of Signum. Signum
has a history of successful grant funding including four NIH SBIRs for skin
therapeutics totaling over US$2.5M. The company is currently in the second
year of a two year US$1.6 M phase II SBIR grant for the development of a
rosacea therapeutic which will enter the clinic next year.

About Signum Biosciences.

Signum Biosciences is a private biotechnology company dedicated to
developing small-molecule therapeutics derived from its Signal Transduction
Modulation (STM) platform to modulate signal transduction imbalances. Through
research on protein networks that control biological systems, Signum is
developing GPCR based therapeutic candidates for skin diseases. Signum's STM
technology provides many opportunities for the development of pharmaceutical
candidates in age-related pathologies.

For more information on Signum and the STM technology, please, visit:
www.signumbiosciences.com

Alex Monteith, Signum Biosciences, +1-732-329-6344, ext. 204